105,000 Shares in Niagen Bioscience, Inc. $NAGE Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. bought a new position in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 105,000 shares of the company’s stock, valued at approximately $980,000. Hussman Strategic Advisors Inc. owned approximately 0.13% of Niagen Bioscience at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Financial Consulate Inc. purchased a new stake in shares of Niagen Bioscience in the 3rd quarter worth approximately $33,000. State of Alaska Department of Revenue purchased a new stake in Niagen Bioscience during the third quarter worth $44,000. North Star Investment Management Corp. bought a new stake in Niagen Bioscience during the 3rd quarter valued at $47,000. KLP Kapitalforvaltning AS bought a new stake in Niagen Bioscience during the 3rd quarter valued at $107,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of Niagen Bioscience in the 3rd quarter valued at $126,000. Institutional investors own 15.41% of the company’s stock.

Analyst Ratings Changes

NAGE has been the subject of a number of analyst reports. Canaccord Genuity Group decreased their price objective on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.28.

Niagen Bioscience Price Performance

Shares of NAGE stock opened at $6.03 on Thursday. The stock’s fifty day moving average price is $6.49 and its 200 day moving average price is $8.00. Niagen Bioscience, Inc. has a 1-year low of $5.25 and a 1-year high of $14.69. The company has a market cap of $481.25 million, a price-to-earnings ratio of 25.13 and a beta of 2.35.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.03. Niagen Bioscience had a return on equity of 24.13% and a net margin of 16.38%.The business had revenue of $33.99 million during the quarter, compared to the consensus estimate of $31.30 million.

Insider Buying and Selling

In related news, CFO Ozan Pamir bought 4,465 shares of the company’s stock in a transaction on Friday, November 14th. The shares were bought at an average price of $6.81 per share, with a total value of $30,406.65. Following the transaction, the chief financial officer owned 7,372 shares in the company, valued at approximately $50,203.32. This trade represents a 153.59% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.39% of the stock is owned by company insiders.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.